HOME >> MEDICINE >> NEWS
GL701 (prasterone) significantly reduces lupus flares

Philadelphia, Pa. - Oct. 31, 2000 - The incidence of debilitating flares or exacerbations that systemic lupus erythematosus (SLE or lupus) patients experience, some resulting in hospitalization, significantly declined with the use of GL701, according to a Phase III placebo-controlled, double-blind multicenter study conducted in Taiwan and presented at the 64th Annual Scientific Meeting of the American College of Rheumatology in Philadelphia. The drug used in this study is similar to Genelabs Technologies, Inc. (Nasdaq:GNLB) formulation of its investigational drug GL701. The study reported here today was conducted by Genelabs Biotechnology Co., Ltd. of Taiwan, a licensee of Genelabs Technologies, Inc.

"GL701 significantly reduced the percent of patients with flares. Since flares can punctuate the remission periods that lupus patients experience, the potential for this investigational drug to increase the duration of remission and decrease the number of flares that require hospitalization is an important therapeutic advance," says Deh-Ming Chang, M.D., coauthor of the study and Professor and Director of Rheumatology/Immunology at the Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

In the study, Chang and his colleagues compared GL701 to placebo among 119 Taiwanese women with lupus. Patients were evaluated in a randomized double-blind comparison of GL701, 200 mg or placebo daily for 24 weeks. Investigators evaluated efficacy based on change in Systemic Lupus Activity Measure (SLAM) and change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), which measure disease activity; physician and patient visual analog scales (VAS), which measure quality of life parameters; and percent of patients with definite flares.

Study results show that 18 percent of patients receiving GL701 experienced flares, compared to 34 percent of patients on placebo, a 46 percent reduction, which was significant (p=0.04). Moreover, no GL701 pa
'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000


Page: 1 2 3

Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a ... and business owners in the greater Dallas metropolitan area, is announcing a charity ... Foundation. , Established in 2009 by active police professionals in the Dallas region, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Sharon Kleyne, host of the nationally ... Your Health on Voice of America, declared on her radio program in November 2016 ... fact that when these bullies attack leaders in corporate America, they are trying to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., ... Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience ... to help patients realize their family building goals. Acupuncture helps fertility patients ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( ... cavernous angiomas, was awarded a grant from the Julian Grace Foundation to increase ... has more people with cavernous angioma than anywhere in the world. Most share ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  Alopexx Oncology, LLC ... a recombinant antibody fusion protein (immunocytokine) composed of interleukin-2 ... the same target on B cells as Rituxan and ... components but is also involved in tumor targeting, engagement ... vaccine effect. The results of the study (abstract #95954) ...
(Date:12/6/2016)... 2016 Homozygous Familial Hypercholesterolemia (HoFH) ... Global Markets Direct,s latest Pharmaceutical and ... (HoFH) – Pipeline Review, H2 2016, provides ... (HoFH) (Metabolic Disorders) pipeline landscape. Homozygous ... is caused due to mutation from both ...
(Date:12/6/2016)... CENTENNIAL, Colo. , Dec. 6, 2016 /PRNewswire-USNewswire/ ... providers of cartilage, cellular, bone, skin and soft-tissue ... Kimberly Meyer , Business Process Manager, for being ... 2016 Malcolm Baldrige National Quality Award by the ... (NIST), deepening the organization,s commitment to process excellence. ...
Breaking Medicine Technology:
Cached News: